Aids ribbon at the White House Mark Wilson/Getty Images

The End of AIDS

The AIDS pandemic claimed some 36 million lives since 1981, and a similar number around the world currently live with the HIV virus. The figures are daunting, but the goal of an “AIDS-free generation” is within reach.

NEW YORK – The AIDS pandemic claimed around 36 million lives between 1981 and 2016, and a similar number around the world currently live with the HIV virus. Some 1.2 million people died of AIDS last year, and another 1.8 million were infected. Those statistics are daunting, but the startling news is that the goal of an “AIDS-Free Generation” is realistically within reach. The required policy steps should be agreed in the early days of US President-elect Donald Trump’s administration.

The key reason that the epidemic can be ended is a scientific finding back in 2011 that showed that HIV-positive individuals receiving antiretroviral (ARV) treatment suppress the HIV virus in their bloodstreams so dramatically that they are very unlikely to transmit the virus to others through sex or shared needles. This finding confirmed the concept of “treatment as prevention.” If a high enough proportion of HIV-positive individuals receive ARV treatment, it is possible not only to save their lives, but also to break the transmission of the virus itself, thereby ending the epidemic.

Building on this idea, AIDS specialists developed two crucial ideas: “90-90-90” and the “cascade of AIDS care.” The 90-90-90 program aims to ensure that by the year 2020, 90% of all HIV-infected individuals know that they are infected (the first 90); 90% of all those who know they are infected are receiving ARV treatment (the second 90); and 90% of all those receiving ARV treatment successfully suppress the HIV virus in the blood. The idea of the cascade is that if each of the three “90s” is achieved, the proportion of all HIV-infected individuals with viral suppression would be 90% x 90% x 90%, which is equal to 72%.

To continue reading, please log in or enter your email address.

To read this article from our archive, please log in or register now. After entering your email, you'll have access to two free articles from our archive every month. For unlimited access to Project Syndicate, subscribe now.


By proceeding, you agree to our Terms of Service and Privacy Policy, which describes the personal data we collect and how we use it.

Log in;

Cookies and Privacy

We use cookies to improve your experience on our website. To find out more, read our updated cookie policy and privacy policy.